Business
Bears vs Texans
This is the closest we could get in the NFL to Bears vs. Bulls. (Photo by Frank Jansky/Icon Sportswire via Getty Images)
Weird Money

NFL franchises and PE firms are a match made in heaven

The two may solve each other's liquidity issues.

Jack Raines

Earlier this week, Bloomberg reported that the NFL is meeting on August 27 to “discuss and potentially vote on allowing institutional investors to buy into teams,” and the NFL hired PJT Partners to “assess private equity interest.”

Assuming that a deal were to come together, it makes a ton of sense for both team owners and private equity firms. The reason? NFL teams are really, really, expensive, and private equity firms need somewhere to invest their capital.

There are 32 NFL franchises, and the average franchise is worth $5.1 billion, up from $423 million (or $773 million in 2023 dollars) in 2000. The NFL requires the majority owner of a team to own a 30% stake in the franchise, which means $1.5 billion, on average. There aren’t that many people who can afford to purchase an NFL team. If we assume that an owner wouldn’t want to spend more than 30% of their own wealth on an NFL franchise, only 214 billionaires in America worth $5.1 billion or more would fit the bill. Taking into account that only some percentage of them would have any interest in owning an NFL team, and that market shrinks even further.

Meanwhile, as noted in my other private equity piece, PE firms are raising more than they know what to do with, and they need assets in which they can invest billions of dollars. NFL franchises are cash-generating machines (18 franchises made more than $100 million in operating income in 2023, and all made more than $50 million), and previous discussions between team owners raised the possibility of institutional investors buying 10% to 30% stakes in companies. A 10% stake in the NFL’s least valuable franchise, the Bengals, would cost $350 million, giving these funds a much-needed destination for their cash and providing interested owners with sought-after liquidity.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.